ATE302015T1 - Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon - Google Patents

Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon

Info

Publication number
ATE302015T1
ATE302015T1 AT95903617T AT95903617T ATE302015T1 AT E302015 T1 ATE302015 T1 AT E302015T1 AT 95903617 T AT95903617 T AT 95903617T AT 95903617 T AT95903617 T AT 95903617T AT E302015 T1 ATE302015 T1 AT E302015T1
Authority
AT
Austria
Prior art keywords
composition
purifying
prevents apoptosis
compositions
methods
Prior art date
Application number
AT95903617T
Other languages
English (en)
Inventor
Ian Cyril Bathurst
John D Bradley
L David Tomei
Philip J Barr
Original Assignee
Sky High Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sky High Llc filed Critical Sky High Llc
Application granted granted Critical
Publication of ATE302015T1 publication Critical patent/ATE302015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
AT95903617T 1993-11-30 1994-11-30 Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon ATE302015T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15898093A 1993-11-30 1993-11-30
US08/320,155 US5759548A (en) 1993-11-30 1994-10-07 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
PCT/US1994/013649 WO1995015173A1 (en) 1993-11-30 1994-11-30 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Publications (1)

Publication Number Publication Date
ATE302015T1 true ATE302015T1 (de) 2005-09-15

Family

ID=26855549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903617T ATE302015T1 (de) 1993-11-30 1994-11-30 Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon

Country Status (14)

Country Link
US (8) US5759548A (de)
EP (1) EP0732930B1 (de)
JP (2) JPH11501284A (de)
KR (1) KR960706350A (de)
CN (1) CN1140998A (de)
AT (1) ATE302015T1 (de)
AU (1) AU678090B2 (de)
CA (1) CA2177825A1 (de)
DE (1) DE69434459T2 (de)
FI (1) FI962246A (de)
HU (1) HUT76096A (de)
NO (1) NO962187L (de)
NZ (1) NZ277403A (de)
WO (1) WO1995015173A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703990A4 (de) * 1993-04-30 1997-09-24 Lxr Biotechnology Inc Verfahren zur erkennung potentiell therapeutisch wirksamer mittel und dafur verwendbare zellinien
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5620888A (en) * 1994-12-29 1997-04-15 Lxr Biotechnology, Inc. Cell strains for use in identifying potentially therapeutically effective agents
EP0850064A1 (de) * 1995-09-14 1998-07-01 Lxr Biotechnology Inc. Anti-apoptose zusammensetzung die eine mischung von phospholipiden enthält
US6197333B1 (en) 1996-03-28 2001-03-06 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
WO1997039722A2 (en) * 1996-04-25 1997-10-30 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
US20070299005A1 (en) 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
DK0932678T4 (da) 1996-09-24 2010-07-12 Genentech Inc En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåder til anvendelse deraf
IL119535A (en) * 1996-10-31 2001-01-11 Chajuss Daniel Soy molasses and modified soy molasses for topical application
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
EP0973384A4 (de) 1997-02-13 2004-10-13 Sky High Llc Organkonservierungslösung
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
AU9027298A (en) * 1997-08-20 1999-03-08 Lxr Biotechnology Inc. Compositions containing polyethylene glycol and uses thereof
EP0911634A1 (de) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmazeutische Verwendungen von Regulatoren der CDK-2
US6949528B1 (en) 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
EP1069895A4 (de) * 1998-03-18 2002-07-31 Lxr Biotechnology Inc Zusammenstellungen die lysophosphatidylsäure enthalten welche apoptosis hemmen und deren verwendungen
US5869063A (en) * 1998-06-29 1999-02-09 Protease Sciences, Inc. Dermatological and cosmetic compositions containing marama bean extract
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6413556B1 (en) * 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
JP2002541237A (ja) * 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AU2580801A (en) * 1999-12-14 2001-06-25 Sky High, Llc Phospholipid compositions as anti-inflammation agents
US20070048726A1 (en) * 2000-01-14 2007-03-01 Biolife Solutions, Inc. Methods and Compositions for the Control of Molecular-Based Cell Death During Preservation of Cells, Tissues or Organs in a Gel-Like State
US20060063738A1 (en) * 2000-02-28 2006-03-23 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use
US6861077B1 (en) * 2000-03-17 2005-03-01 L'oreal S.A. Use of plant extracts in a cosmetic composition to protect keratinous fibers
CA2458068A1 (en) * 2001-08-20 2003-02-27 Tatton Technologies, Llc. Methods and compositions for treating apoptosis associated disorders
US20030077264A1 (en) * 2001-09-20 2003-04-24 Goodrich Laura L. Antimicrobial blood treatment using allicin and related compounds
EP2298278B1 (de) * 2002-06-07 2015-11-11 Dyax Corp. Verhinderung und Reduzierung von Blutverlust und Entzündungsreaktion
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
SI2386310T1 (sl) * 2002-08-28 2019-03-29 Dyax Corp. Metode za ohranjanje organov in tkiv
EP1537249B1 (de) * 2002-09-13 2014-12-24 GBC Metals, LLC AUSSCHEIDUNGSHûRTENDE KUPFERBASISLEGIERUNG
EP1398019A1 (de) 2002-09-13 2004-03-17 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US7829277B2 (en) 2004-03-01 2010-11-09 The Regents Of The University Of California Methods for identifying compounds that suppress chemically-induced carcinogenesis
US20060035827A1 (en) * 2004-06-24 2006-02-16 Green Gary M Compositions and methods for the treatment or prevention of gallbladder disease
US7691417B2 (en) 2004-09-02 2010-04-06 Clemson University Research Foundation Tumor and mutation suppressing plant extract
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US8187643B2 (en) * 2007-03-28 2012-05-29 Greg Steininger, legal representative Shampoo formulation for treatment of hair loss and method of use
WO2010005560A2 (en) * 2008-07-07 2010-01-14 Woods Hole Oceanographic Institution Methods for obtaining bioactive compounds from phytoplankton
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US9217741B2 (en) * 2009-11-05 2015-12-22 Woods Hole Oceangraphic Institution Bioactive compounds from phytoplankton containing glycosidic residue for apoptosis and cancer treatment
CA2780177A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
BR112013017080A8 (pt) 2011-01-06 2023-05-09 Dyax Corp Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) * 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
JPH0611709B2 (ja) * 1984-10-19 1994-02-16 チロン コーポレイション 角膜基質創傷の治療のための組成物
US4793996A (en) * 1984-11-14 1988-12-27 Ann R. Kennedy Method of making soybean extract inhibitor
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
JPS62155082A (ja) * 1985-12-27 1987-07-10 Karupisu Shokuhin Kogyo Kk ビフイズス菌増殖物質の製造法
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
JPS6351335A (ja) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd 肥満細胞脱顆粒抑制剤
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US4959310A (en) * 1987-09-28 1990-09-25 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to soybean kunitz trypsin inhibitor and immunoassay methods
US5053327A (en) * 1988-09-20 1991-10-01 The United States Of America As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies to bowman-birk inhibitor and immunoassay methods
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JP2809429B2 (ja) * 1989-05-26 1998-10-08 湧永製薬株式会社 制ガン剤ならびに制ガン剤として有用な新規複素環化合物またはそれらの塩
US5217717A (en) * 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
US5376373A (en) * 1990-09-06 1994-12-27 Trustees Of The University Of Pennsylvania Method of inhibiting radiation induced weight and hair loss
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
US5340568A (en) * 1992-07-01 1994-08-23 The Procter & Gamble Company Topical composition and method containing deoxy and halo derivatives of lysophosphatidic acids for regulating skin wrinkles
US5636187A (en) 1992-12-11 1997-06-03 Canon Kabushiki Kaisha Magnetooptical recording apparatus and magnetooptical recording method for canceling leakage magnetic fields associated with a recording medium and devices ancillary to the recording medium
US5277917A (en) * 1993-04-02 1994-01-11 Allelix Biopharmaceuticals Inc. Ovarian cancer ascites factor, in isolated form
EP0703990A4 (de) * 1993-04-30 1997-09-24 Lxr Biotechnology Inc Verfahren zur erkennung potentiell therapeutisch wirksamer mittel und dafur verwendbare zellinien
US5330972A (en) * 1993-05-28 1994-07-19 Abbott Laboratories Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
NZ248603A (en) * 1993-05-28 1994-12-22 Abbott Lab Nutritional product for enteral nutritional support of hiv victims comprising proteins and fat
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Also Published As

Publication number Publication date
US5624672A (en) 1997-04-29
DE69434459D1 (de) 2005-09-22
FI962246A0 (fi) 1996-05-29
US20020110608A1 (en) 2002-08-15
JP2007084573A (ja) 2007-04-05
EP0732930B1 (de) 2005-08-17
NO962187L (no) 1996-07-30
NZ277403A (en) 1998-03-25
WO1995015173A1 (en) 1995-06-08
US6656729B2 (en) 2003-12-02
US6306398B1 (en) 2001-10-23
NO962187D0 (no) 1996-05-29
US5635186A (en) 1997-06-03
EP0732930A1 (de) 1996-09-25
DE69434459T2 (de) 2006-04-06
AU1261295A (en) 1995-06-19
US5759548A (en) 1998-06-02
US5620885A (en) 1997-04-15
AU678090B2 (en) 1997-05-15
FI962246A (fi) 1996-07-22
CA2177825A1 (en) 1995-06-08
HU9601449D0 (en) 1996-07-29
EP0732930A4 (de) 1997-10-29
JPH11501284A (ja) 1999-02-02
US5635187A (en) 1997-06-03
US5567425A (en) 1996-10-22
KR960706350A (ko) 1996-12-09
CN1140998A (zh) 1997-01-22
HUT76096A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
ATE302015T1 (de) Zusammensetzung, welche apoptosis verhindert, methode zur reinigung dieser zusammensetzung und verwendungen davon
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
BR9900320A (pt) Composição antimicrobiana
DE69831566T2 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
BG102818A (en) D-manitol and method for its preparation
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ITMI931649A1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
DE60235836D1 (de) Ahren und verwendung davon
ATE302613T1 (de) Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
ATE283044T1 (de) Compactin zur behandlung von entzündungen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69614824T2 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
ATE82867T1 (de) Verfahren zur feuerbekaempfung und anwendung dieses verfahrens.
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ES2082212T3 (es) Nuevos inhibidores de alfa-glucosidasa.
DE50010972D1 (de) UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties